NeuroPace CEO granted RSUs and options
NeuroPace Inc CEO Joel Becker reported equity awards consisting of restricted stock units and stock options.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
NeuroPace Inc CEO Joel Becker reported equity awards consisting of restricted stock units and stock options. He received 45,880 RSU-based shares of common stock, bringing his common stock holdings to 142,817 shares. He was also granted options on 122,190 shares at an exercise price of $15.36, expiring on May 14, 2036.
The RSUs vest 25% on May 15, 2027, with the remainder in twelve equal quarterly installments. The stock options vest 25% on May 15, 2027, with the remaining shares vesting in thirty-six equal monthly installments thereafter.
Insider Trade Summary
Grant/Award: 168,070 shares
Grant/Award
2 txns
Insider
Becker Joel
Role
CHIEF EXECUTIVE OFFICER
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 122,190 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 45,880 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 122,190 contracts (Direct);
Common Stock — 142,817 shares (Direct)
Footnotes (2)
- F1. Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement. 25% of the RSUs vest on May 15, 2027 and the remaining RSUs vest in twelve (12) equal quarterly installments thereafter.
- F2. 25% of the shares subject to the option vest on May 15, 2027. The remaining shares subject to the option vest in thirty six (36) equal consecutive monthly installments thereafter.
Key Figures
RSU grant size: 45,880 shares
Common shares held after grant: 142,817 shares
Stock options granted: 122,190 options
+4 more
7 metrics
RSU grant size
45,880 shares
Restricted stock units representing common stock granted to CEO
Common shares held after grant
142,817 shares
Direct common stock ownership following RSU grant
Stock options granted
122,190 options
Options on common stock granted to CEO
Option exercise price
$15.36 per share
Conversion or exercise price for newly granted stock options
Option expiration date
May 14, 2036
Expiration of stock options on 122,190 shares
Initial RSU vesting date
May 15, 2027
25% of RSUs vest on this date
Initial option vesting date
May 15, 2027
25% of options vest on this date
Key Terms
restricted stock unit ("RSU"), contingent right, Stock Option (Right to Buy), vest, +1 more
5 terms
restricted stock unit ("RSU") financial
"Each share is represented by a restricted stock unit ("RSU")."
contingent right financial
"Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement."
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy)"
vest financial
"25% of the RSUs vest on May 15, 2027 and the remaining RSUs vest in twelve (12) equal quarterly installments thereafter."
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
exercise price financial
"conversion_or_exercise_price: "15.3600""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did NeuroPace (NPCE) CEO Joel Becker report in this Form 4?
Joel Becker reported equity awards of RSUs and stock options. He received 45,880 RSU-based common shares and options on 122,190 shares, all as grants with no cash purchase, increasing his reported direct equity exposure in NeuroPace.
What are the key terms of Joel Becker’s NeuroPace RSU grant?
The RSU grant covers 45,880 common shares. Each restricted stock unit represents one share upon settlement. Twenty-five percent vest on May 15, 2027, and the remaining units vest in twelve equal quarterly installments after that initial vesting date.
What are the vesting terms of Joel Becker’s NeuroPace stock options?
The option grant covers 122,190 shares at a $15.36 exercise price. Twenty-five percent of these options vest on May 15, 2027. The remaining options vest in thirty-six equal consecutive monthly installments following that date, subject to continued vesting conditions.
When do Joel Becker’s newly granted NeuroPace stock options expire?
The stock options granted to Joel Becker expire on May 14, 2036. They are exercisable for 122,190 underlying common shares at an exercise price of $15.36, following the specified vesting schedule beginning on May 15, 2027.
Is Joel Becker’s Form 4 transaction a market purchase or a compensation grant?
The transactions are compensation-related grants, not open-market purchases. Both the 45,880 RSU-based shares and the 122,190 stock options were reported with a zero purchase price and classified as grant or award acquisitions under transaction code A.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates